Language: 简体中文 English
Zhongze Gu
Zhongze Gu, Ph.D.
State Key Laboratory of Bioelectronics,
School of Biological Science and Medical Engineering,
Southeast University,
Sipailou 2, Nanjing, Jiangsu 210096, China
Tel: +86-25-83795635


Dr. Zhongze Gu graduated from Southeast University (China) in 1989 and got his M.S. in 1992 there. He went to The University of Tokyo (Japan) in 1994 and obtained his Ph.D. in 1998. Since then, he had been working as a researcher at the Kanagawa Academy of Science and Technology. He then began a project to study the opal photonic crystals and made a lot of excellent work in this field. Since 2003, he began to work at Southeast University as a professor Cheung Kong Scholars of Biomedical Science and Medical Engineering. Now he is the dean of School of Biological Science and Medical Engineering, the director of State Key Laboratory of Bioelectronics. His researches related to bio-inspired intelligent materials, photonic crystal, biosensor and bioelectronics. He has published more than two hundred research papers in international journals and applied more than 70 related patents.

Advanced 3D Printing System and Automated Detection System for Organs-on-a-Chip

Organs-on-a-chip system, or microphysiological system (MPS), is a new type of biomedical research method that aims to recapitulate organ-level tissue structures and functions for drug evaluation and disease modeling. The MPS can be used to simulate the microstructure, microenvironment, and functional features of human organs, and apply in drug screening and clinical diagnosis and treatment. In previous study, we have developed multiple organ-on-a-chip systems including biomimetic blood vessels, kidney, liver, heart, etc. [1-2] Our previous work demonstrated that the miniature organs made with advanced microfabrication, 3D printing, microfluidics and tissue engineering techniques could form tissue-specific structures and could maintain some desirable organ functions for more than four weeks [3-5].
In this work, we report development of a tumor-on-a-chip system for automated oncology drug screening. In current preclinical oncology drug development, 2D-cultured cell models cannot accurately predict drug efficacy in vivo, while animal models are expensive and low-throughput. Further, neither model is able to assess cancer cell migration and metastasis data in real-time effectively. Our technology offers the packaged solutions to solve the problems above by providing the 3D in vitro tumor-on-a-chip system including creating tumor spheroids (TSs), constructing 3D-microenviroments and fine 3D-structures with two-photon printing at a resolution ~150nm, imaging TSs with an automated system, and analyzing TSs using multiple AI-algorisms. This system has a standardized multi-well setup (96 or 384) thus is convenient for customer’s usage and application in high-throughput drug screenings. This system will enable drug developers to monitor cancer cell viability, migration and metastasis quantitatively and automatically.

  • DAYS
Key Dates
   Deadline for Submission of Abstract:
  October 31, 2018
   Notification of abstract acceptance:
   November 15, 2018